KACEY INSULIN SYRINGE

K033166 · Kacey, Inc. · FMF · Dec 12, 2003 · General Hospital

Device Facts

Record IDK033166
Device NameKACEY INSULIN SYRINGE
ApplicantKacey, Inc.
Product CodeFMF · General Hospital
Decision DateDec 12, 2003
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 880.5860
Device ClassClass 2
AttributesTherapeutic

Intended Use

This product is intended for use by individuals who have been directed by and are under the supervision of professional staff to use insulin injections as a means to control the effects of diabetes. The product is intended to be used in any setting that meets the needs of the user.

Device Story

Kacey Insulin Syringe is a piston syringe used for subcutaneous insulin delivery. Device enables patients to self-administer insulin to manage diabetes under professional guidance. Operates via manual plunger depression to displace insulin through an attached needle. Used in home or clinical settings. Provides a simple, mechanical method for accurate insulin dosing; facilitates glycemic control.

Clinical Evidence

No clinical data; bench testing only.

Technological Characteristics

Piston syringe design. Manual operation. Materials and dimensions consistent with standard insulin syringe specifications for 880.5860 regulation. Non-electronic, mechanical device.

Indications for Use

Indicated for individuals requiring insulin injections to manage diabetes, under professional supervision. Suitable for use in any setting.

Regulatory Classification

Identification

A piston syringe is a device intended for medical purposes that consists of a calibrated hollow barrel and a movable plunger. At one end of the barrel there is a male connector (nozzle) for fitting the female connector (hub) of a hypodermic single lumen needle. The device is used to inject fluids into, or withdraw fluids from, the body.

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is an abstract symbol that resembles an eagle or bird in flight, composed of three curved lines. Public Health Service Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 DEC 1 2 2003 Dr. Charles F. Neilson, PhD Scientific Affairs Kacey, Incorporated 715 Buckeye Terrace Rock Hill South Carolina Re: K033166 Trade/Device Name: Kacey Insulin Syringe Regulation Number: 880.5860 Regulation Name: Piston Syringe Regulatory Class: II Product Code: FMF Dated: September 26, 2003 Received: September 30, 2003 Dear Dr. Neilson: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. {1}------------------------------------------------ Page 2 - Mr. Neilson Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4618 . Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its tollfree number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html Sincerely yours, Susan Runner Chiu Lin, Ph.D. Director Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {2}------------------------------------------------ ## INDICATION FOR USE KRCCy Device Name - HETHMA Device Description - Piston Syringe This product is intended for use by individuals who have been directed by and are under the supervision of professional staff to use insulin injections as a means to control the effects of diabetes. The product is intended to be used in any setting that meets the needs of the user. Patricio Cucente Division Sian-Off Division of Anesthesiology, General Hospital, ction Control, Denta 510(k) Number: K033166 (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) Prescription Use (Per 21 CFR 801.109) 1 ાર Over-The-Counter Use_\$\swarrow\$ (Optional Format 1-2-96)
Innolitics
510(k) Summary
Decision Summary
Classification Order
Enter a record ID and click Load to view the document.
100%